Efficacy and safety of a hexanic extract of Serenoa repens (Permixon( ) ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies.
Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A, Miñana López B, Fernández-Gómez JM, Angulo JC, Castro Díaz D, Romero-Otero J, Brenes FJ, Carballido J, Molero García JM, Fernández-Pro Ledesma A, Cózar Olmos JM, Manasanch Dalmau J, Subirana Cachinero I, Herdman M, Ficarra V.
Vela-Navarrete R, et al.
BJU Int. 2018 Dec;122(6):1049-1065. doi: 10.1111/bju.14362. Epub 2018 Jun 6.
BJU Int. 2018.
PMID: 29694707
Free article.
OBJECTIVES: To comprehensively evaluate the efficacy and safety of the hexanic extract of Serenoa repens (HESr, Permixon( ) ; Pierre Fabre Medicament, Castres, France), at a dose of 320 mg daily, as monotherapy for the treatment of lower urinary tract symptoms assoc …
OBJECTIVES: To comprehensively evaluate the efficacy and safety of the hexanic extract of Serenoa repens (HESr, Permixon( ) ; …